The Europe animal health market size was estimated at USD 62.48 billion in 2025 and is predicted to increase from USD 67.45 billion in 2026 to approximately USD 134.39 billion by 2035, expanding at a CAGR of 7.96% from 2026 to 2035. Growing pet humanization trends, increasing demand for animal monoclonal antibody therapies, a shift towards preventive veterinary vaccines, growing pet ownership, increasing zoonotic diseases, growing sustainability initiatives, expanding pet insurance policies, and increasing investments are promoting the market growth.
The Europe animal health refers to the development, manufacturing, and sale of veterinary products which are used for animal disease diagnosis, treatment, control, and prevention. They help in enhancing animal health, wellness, food safety, the prevention of various diseases, and enhancing livestock productivity. They also focus on animal nutrition support, behavioural health, operative care, surgical care, and dental care.
The graph represents a comparison between the veterinary medicines authorised in Europe in the year 2025. It indicates that there will be a rise in the developmnet of new veterinary products for effective diagnosis and treatment of growing animal diseases. This, in turn, will enhance animal healthcare across Europe, which will ultimately promote the market growth.
By product type, the pharmaceuticals segment accounted for the highest revenue share of 38% of the Europe animal health market in 2025, due to growth in animal diseases. The growth in preventive veterinary care also increased the use of vaccines and parasiticides. Expansion in pet ownership and stringent animal health regulations also increased their adoption.
By animal type, the companion animals segment held a major revenue share of 58% of the Europe animal health market in 2025, driven by increasing pet humanization and ownership. High pet healthcare spending and frequent veterinary visits also increased the demand for advanced animal health solutions. Rise in pet grooming and premium pet care products also contributed to their expansion.
By indication type, the infectious diseases segment contributed the biggest revenue share of 29% of the Europe animal health market in 2025, due to growth in their prevalence rate. Their frequent outbreaks and shift towards early disease diagnosis also increased the demand for advanced diagnostic products. Stringent animal disease control regulations also increased the demand for various pharmaceuticals.
By distribution channel type, the veterinary hospitals & clinics segment held the largest revenue share of 44% of the Europe animal health market in 2025, driven by high pet owner trust. Direct access to veterinarians' guidance and access to prescription-based products also increased their acceptance rates. Availability of a wide range of products and advanced facilities also increased their preference.
By end user, the veterinary hospitals segment led the Europe animal health market with 33% share in 2025, driven by a high volume of animal visits. Their advanced diagnostic, treatment, and preventive care options also attracted the pet owners. The presence of skilled veterinarians and a multispecialty veterinary network also increased their use.
Europe animal health market held a considerable share in 2025 and is expected to show lucrative growth during the predicted time, due to stringent regulations and growth in pet ownership. Rise in pet humanization trends and disease outbreaks also increased the demand for various animal health products. Expansions of veterinary hospitals, preventive healthcare, government support, and tele-veterinary services are also enhancing the market growth.
Zoetis Inc. registered dominance over the market with its Cytopoint, Librela, Apoquel, and Solensia, where Boehringer Ingelheim Animal Health was its closest competitor, which offered NexGard, Metacam, Ingelvac Circoflex, and Frontline. MSD Animal Health also sustained its position by offering Bravecto, Bovilis, and Nobivac, where Ceva Sante Animale also contributed to the market growth with its Feliway, Cardalis, Cevac, and Adaptil products.
By Product Type
By Animal Type
By Indication
By Distribution Channel
By End User
By Route of Administration
By Region
